Analysts raise Centene price targets to $75 and $71
Cantor Fitzgerald analyst Sarah James maintained an Overweight rating on Centene and raised the price target to $75 from $60. RBC Capital analyst Ben Hendrix maintained a Sector Perform rating and increased the price target to $71 from $70.
*this image is generated using AI for illustrative purposes only.
Cantor Fitzgerald and RBC Capital have both raised their price targets for Centene (NYSE: CNC), reflecting a positive outlook for the healthcare company's stock performance. Cantor Fitzgerald analyst Sarah James increased the target to $75 from $60 while maintaining an Overweight rating. Separately, RBC Capital analyst Ben Hendrix lifted the target to $71 from $70 with a Sector Perform rating.
The revised targets suggest confidence in Centene's business fundamentals and growth trajectory. Cantor Fitzgerald's increase to $75 represents a significant jump from the previous estimate of $60, while RBC Capital's adjustment to $71 indicates a modest upward revision.
| Firm | Analyst | Rating | Previous Target | New Target |
|---|---|---|---|---|
| Cantor Fitzgerald | Sarah James | Overweight | $60 | $75 |
| RBC Capital | Ben Hendrix | Sector Perform | $70 | $71 |
Centene continues to be monitored by market analysts for its operational efficiency and market position.
What specific operational improvements are driving Cantor Fitzgerald's aggressive price target increase?
How might Centene's market position evolve relative to competitors given these revised targets?
What upcoming regulatory changes could impact Centene's growth trajectory in the healthcare sector?
20
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
